Amgens bite antibody blinatumomab (amg 103) achieved high rate of complete response in adult patients with relapsed or refractory acute lymphoblastic leukemia Full Text
Amgen announced updated results from a Phase 2 study that showed treatment with blinatumomab (AMG 103) helped achieve a high–rate of complete response (CR) in 72 percent of adult patients with relapsed or refractory B–precursor acute lymphoblastic leukemia (ALL) treated in the study. Blinatumomab is the first of a new class of agents called bi–specific T cell engagers (BiTE) antibodies, designed to harness the body's cell–destroying T cells to kill cancer cells. Blinatumomab targets cells expressing CD19, a protein found on the surface of B–cell derived leukemias and lymphomas, such as ALL. Full results of the study will be presented during an oral abstract session at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) on June 4 (Abstract Number 6500; Oral Presentation.